• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Vector Group Reports First Quarter 2024 Financial Results

    5/1/24 4:17:00 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $VGR alert in real time by email

    Continued Strong Earnings Growth in Tobacco Segment

    First Quarter 2024 Highlights:

    • Consolidated revenues of $324.6 million, down 2.9% or $9.6 million compared to the prior year period.
      • Tobacco segment revenues of $324.6 million, down 2.9% or $9.6 million compared to the prior year period.
      • Tobacco segment wholesale market share declined to 5.6% from 5.7% in the prior year period and retail market share remained at 5.8%, unchanged from the prior year period.
      • Montego wholesale market share increased to 3.9% from 3.3% in the prior year period and retail market share increased to 4.0% from 3.4% in the prior year period.
    • Reported operating income of $77.8 million, up 4.7% or $3.5 million compared to the prior year period.
      • Tobacco segment operating income of $83.0 million, up 5.6% or $4.4 million compared to the prior year period, primarily attributable to the continued transition of the Montego brand strategy from volume-based to income-based.
    • Adjusted EBITDA of $82.8 million, up 6.0% or $4.7 million compared to the prior year period.
      • Tobacco Adjusted EBITDA of $84.4 million, up 5.5% or $4.4 million compared to the prior year period.

    Vector Group Ltd. (NYSE:VGR) today announced financial results for the three months ended March 31, 2024.

    "Vector Group delivered strong performance in the first quarter driven by continued growth of our Montego brand," said Howard M. Lorber, President and Chief Executive Officer of Vector Group Ltd. "Our proven ability to increase Montego's market share and profitability underscores the effectiveness of our brand strategy, market analysis, broad-based distribution, and excellent retail execution. We remain confident in our ability to continue driving sustainable growth and creating long-term value for our stockholders."

    GAAP Financial Results

    Three months ended March 31, 2024 and 2023

    For the three months ended March 31, 2024 revenues were $324.6 million, compared to revenues of $334.1 million for the first quarter of 2023. The Company recorded operating income of $77.8 million for the first quarter of 2024 compared to $74.3 million for the first quarter of 2023. Net income for the first quarter of 2024 was $34.8 million, or $0.22 per diluted common share, compared to net income of $34.7 million, or $0.22 per diluted common share, for the first quarter of 2023.

    Non-GAAP Financial Measures

    Three months ended March 31, 2024 compared to the three months ended March 31, 2023

    Adjusted EBITDA (as described in Table 2 attached hereto) were $82.8 million for the first quarter of 2024, compared to $78.1 million for the first quarter of 2023.

    Adjusted Net Income (as described in Table 3 attached hereto) was $37.2 million, or $0.24 per diluted common share, for the first quarter of 2024, compared to $34.0 million, or $0.22 per diluted common share, for the first quarter of 2023.

    Adjusted Operating Income (as described in Table 4 attached hereto) was $77.8 million for the first quarter of 2024, compared to $74.3 million for the first quarter of 2023.

    Consolidated Balance Sheet

    Vector Group maintained significant liquidity at March 31, 2024 with cash and cash equivalents of $333 million, including $84 million of cash at Liggett. Vector Group also held investment securities of $129 million and long-term investments of $50 million.

    Vector Group continued its longstanding practice of paying a quarterly cash dividend in the first quarter of 2024, returning $32 million to stockholders at a rate of $0.20 per common share.

    Tobacco Segment Financial Results

    For the first quarter of 2024, the Tobacco segment had revenues of $324.6 million, compared to $334.1 million for the first quarter of 2023.

    Operating Income from the Tobacco segment was $83.0 million for the first quarter of 2024, compared to $78.6 million for the first quarter of 2023.

    Non-GAAP Financial Measures

    Tobacco Adjusted Operating Income (as described in Table 5 attached hereto) was $83.0 million for the first quarter of 2024, compared to $78.6 million for the first quarter of 2023.

    Operational Metrics

    For the three months ended March 31, 2024, the Tobacco segment had conventional cigarette (wholesale) shipments of approximately 2.10 billion units, compared to 2.35 billion units for the first quarter of 2023.

    According to data from Management Science Associates, Inc., for the first quarter of 2024, the Tobacco segment's wholesale market share declined to 5.6% from 5.7% for the first quarter of 2023. The Tobacco segment's wholesale market share was 5.5% for the last twelve months ended March 31, 2024. For the three months ended March 31, 2024, Montego's wholesale market share increased to 3.9%, from 3.3% for the three months ended March 31, 2023. Compared to the first quarter of 2023, the Tobacco segment's wholesale shipments in the first quarter of 2024 declined by 10.7%, while the industry's overall wholesale shipments declined by 9.8%.

    According to data from Management Science Associates, for the first quarter of 2024, the Tobacco segment's retail market share remained stable at 5.8% compared to the first quarter of 2024. The Tobacco segment's retail market share is 5.8% for the last twelve months ended March 31, 2024. For the three months ended March 31, 2024, Montego's retail market share increased to 4.0%, from 3.4% for the three months ended March 31, 2023. Compared to the first quarter of 2023, the Tobacco segment's retail shipments in the first quarter of 2024 declined by 8.7% while the industry's overall retail shipments declined by 8.9%.

    Non-GAAP Financial Measures

    Adjusted EBITDA, Adjusted Net Income, Adjusted Operating Income, Tobacco Adjusted Operating Income, and Tobacco Adjusted EBITDA (the "Non-GAAP Financial Measures") are financial measures not prepared in accordance with generally accepted accounting principles ("GAAP"). The Company believes that the Non-GAAP Financial Measures are important measures that supplement discussions and analysis of its results of operations and enhance an understanding of its operating performance. The Company believes the Non-GAAP Financial Measures provide investors and analysts with a useful measure of operating results unaffected by differences in capital structures and ages of related assets among otherwise comparable companies.

    Management uses the Non-GAAP Financial Measures as measures to review and assess operating performance of the Company's business, and management does and investors should review both the overall performance (GAAP net income) and the operating performance (the Non-GAAP Financial Measures) of the Company's business. While management considers the Non-GAAP Financial Measures to be important, they should be considered in addition to, but not as substitutes for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating income, net income and cash flows from operations. In addition, the Non-GAAP Financial Measures are susceptible to varying calculations and the Company's measurement of the Non-GAAP Financial Measures may not be comparable to those of other companies.

    Reconciliations of Non-GAAP Financial Measures to the comparable GAAP financial results for the last twelve months ended March 31, 2024 and the three months ended March 31, 2024 and 2023 are included in Tables 2 through 6.

    Conference Call to Discuss First Quarter 2024 Results

    As previously announced, Vector Group will host a conference call and webcast on Thursday, May 2, 2024 at 8:00AM (ET) to discuss its first quarter 2024 results. Investors can access the call via webcast at https://www.webcaster4.com/Webcast/Page/2271/50471. Please join the webcast at least 10 minutes prior to the start time.

    A replay of the call will be available shortly after the call ends on May 2, 2024 through May 16, 2024 at https://www.webcaster4.com/Webcast/Page/2271/50471.

    About Vector Group Ltd.

    Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC, and New Valley LLC. Additional information concerning the Company is available on the Company's website, www.VectorGroupLtd.com.

    Investors and others should note that we may post information about the Company or its subsidiaries on our website at www.VectorGroupLtd.com and/or at the websites of those subsidiaries or, if applicable, on their accounts on LinkedIn, TikTok, X or other social media platforms. It is possible that the postings or releases could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.VectorGroupLtd.com, on the websites of our subsidiaries and on their social media accounts.

    Forward-Looking and Cautionary Statements

    This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," "estimate," "expect," "intend," "may be," "continue," "could," "potential," "objective," "plan," "seek," "predict," "project" and "will be" and similar words or phrases or their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual results could differ materially for a variety of reasons.

    Risks and uncertainties that could cause our actual results to differ significantly from our current expectations are described in our 2023 Annual Report on Form 10-K and, when filed, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.

    [Financial Tables Follow]

     

    TABLE 1

    VECTOR GROUP LTD. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (Unaudited)

    (Dollars in Thousands, Except Per Share Amounts)

     

     

    Three Months Ended

     

    March 31,

     

     

    2024

     

     

     

    2023

     

    Revenues:

     

     

     

    Tobacco*

    $

    324,567

     

     

    $

    334,145

     

     

     

     

     

    Expenses:

     

     

     

    Cost of sales:

     

     

     

    Tobacco*

     

    217,901

     

     

     

    232,286

     

     

     

     

     

    Operating, selling, administrative and general expenses

     

    28,694

     

     

     

    27,292

     

    Litigation settlement and judgment expense

     

    191

     

     

     

    270

     

    Operating income

     

    77,781

     

     

     

    74,297

     

     

     

     

     

    Other income (expenses):

     

     

     

    Interest expense

     

    (27,449

    )

     

     

    (27,474

    )

    Loss on extinguishment of debt

     

    —

     

     

     

    (141

    )

    Equity in earnings (losses) from investments

     

    2,138

     

     

     

    (159

    )

    Equity in losses from real estate ventures

     

    (10,721

    )

     

     

    (1,893

    )

    Other, net

     

    6,385

     

     

     

    3,620

     

    Income before provision for income taxes

     

    48,134

     

     

     

    48,250

     

    Income tax expense

     

    13,334

     

     

     

    13,509

     

     

     

     

     

    Net income

    $

    34,800

     

     

    $

    34,741

     

     

     

     

     

    Per basic common share:

     

     

     

     

     

     

     

    Net income applicable to common shares

    $

    0.22

     

     

    $

    0.22

     

     

     

     

     

    Per diluted common share:

     

     

     

     

     

     

     

    Net income applicable to common shares

    $

    0.22

     

     

    $

    0.22

     

     

    * Revenues and cost of sales include federal excise taxes of $105,823 and $117,818 for the three months ended March 31, 2024 and 2023, respectively.

    TABLE 2

    VECTOR GROUP LTD. AND SUBSIDIARIES

    RECONCILIATION OF ADJUSTED EBITDA

    (Unaudited)

    (Dollars in Thousands)

     

     

    LTM

     

    Year Ended

     

    Three Months Ended

     

    March 31,

     

    December 31,

     

    March 31,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

     

    Net income

    $

    183,585

     

     

    $

    183,526

     

     

    $

    34,800

     

     

    $

    34,741

     

    Interest expense

     

    108,592

     

     

     

    108,617

     

     

     

    27,449

     

     

     

    27,474

     

    Income tax expense

     

    64,751

     

     

     

    64,926

     

     

     

    13,334

     

     

     

    13,509

     

    Depreciation and amortization

     

    6,882

     

     

     

    6,941

     

     

     

    1,633

     

     

     

    1,692

     

    EBITDA

    $

    363,810

     

     

    $

    364,010

     

     

    $

    77,216

     

     

    $

    77,416

     

    Equity in (earnings) losses from investments (a)

     

    (3,559

    )

     

     

    (1,262

    )

     

     

    (2,138

    )

     

     

    159

     

    Equity in losses (earnings) from real estate ventures (b)

     

    6,626

     

     

     

    (2,202

    )

     

     

    10,721

     

     

     

    1,893

     

    Loss on extinguishment of debt

     

    408

     

     

     

    549

     

     

     

    —

     

     

     

    141

     

    Stock-based compensation expense (c)

     

    11,319

     

     

     

    10,111

     

     

     

    3,314

     

     

     

    2,106

     

    Litigation settlement and judgment expense (d)

     

    18,720

     

     

     

    18,799

     

     

     

    191

     

     

     

    270

     

    Impact of MSA settlement (e)

     

    (592

    )

     

     

    (734

    )

     

     

    (169

    )

     

     

    (311

    )

    Other, net

     

    (28,884

    )

     

     

    (26,119

    )

     

     

    (6,385

    )

     

     

    (3,620

    )

    Adjusted EBITDA

    $

    367,848

     

     

    $

    363,152

     

     

    $

    82,750

     

     

    $

    78,054

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA by Segment

     

     

     

     

     

     

     

    Tobacco

    $

    375,003

     

     

    $

    370,575

     

     

    $

    84,390

     

     

    $

    79,962

     

    Real Estate

     

    222

     

     

     

    313

     

     

     

    (29

    )

     

     

    62

     

    Corporate and Other

     

    (7,377

    )

     

     

    (7,736

    )

     

     

    (1,611

    )

     

     

    (1,970

    )

    Total

    $

    367,848

     

     

    $

    363,152

     

     

    $

    82,750

     

     

    $

    78,054

     

    ____________

    a.

     

    Represents equity in (earnings) losses recognized from investments that the Company accounts for under the equity method.

    b.

     

    Represents equity in losses (earnings) recognized from the Company's investment in certain real estate ventures that are accounted for under the equity method and are not consolidated in the Company's financial results.

    c.

     

    Represents amortization of stock-based compensation.

    d.

     

    Represents accruals for litigation in the Tobacco segment.

    e.

     

    Represents the Tobacco segment's settlement of long-standing disputes related to the Master Settlement Agreement.

     

    TABLE 3

    VECTOR GROUP LTD. AND SUBSIDIARIES

    RECONCILIATION OF ADJUSTED NET INCOME

    (Unaudited)

    (Dollars in Thousands, Except Per Share Amounts)

     

     

    Three Months Ended

     

    March 31,

     

     

    2024

     

     

     

    2023

     

     

     

    Net income

    $

    34,800

     

     

    $

    34,741

     

     

     

     

     

    Loss on extinguishment of debt

     

    —

     

     

     

    141

     

    Litigation settlement and judgment expense (a)

     

    191

     

     

     

    270

     

    Impact of MSA settlement (b)

     

    (169

    )

     

     

    (311

    )

    Impact of net interest expense capitalized to real estate ventures

     

    3,218

     

     

     

    (1,041

    )

    Total adjustments

     

    3,240

     

     

     

    (941

    )

     

     

     

     

    Tax expense (benefit) related to adjustments

     

    (818

    )

     

     

    243

     

     

     

     

     

    Adjusted Net Income

    $

    37,222

     

     

    $

    34,043

     

     

     

     

     

    Per diluted common share:

     

     

     

     

     

     

     

    Adjusted Net Income applicable to common shares

    $

    0.24

     

     

    $

    0.22

     

    ____________

    a.

     

    Represents accruals for litigation in the Tobacco segment.

    b.

     

    Represents the Tobacco segment's settlement of long-standing disputes related to the Master Settlement Agreement.

     

    TABLE 4

    VECTOR GROUP LTD. AND SUBSIDIARIES

    RECONCILIATION OF ADJUSTED OPERATING INCOME

    (Unaudited)

    (Dollars in Thousands)

     

     

    LTM

     

    Year Ended

     

    Three Months Ended

     

    March 31,

     

    December 31,

     

    March 31,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

     

    Operating income

    $

    331,519

     

     

    $

    328,035

     

     

    $

    77,781

     

     

    $

    74,297

     

     

     

     

     

     

     

     

     

    Litigation settlement and judgment expense (a)

     

    18,720

     

     

     

    18,799

     

     

     

    191

     

     

     

    270

     

    Impact of MSA settlement (b)

     

    (592

    )

     

     

    (734

    )

     

     

    (169

    )

     

     

    (311

    )

    Total adjustments

     

    18,128

     

     

     

    18,065

     

     

     

    22

     

     

     

    (41

    )

     

     

     

     

     

     

     

     

    Adjusted Operating Income

    $

    349,647

     

     

    $

    346,100

     

     

    $

    77,803

     

     

    $

    74,256

     

    ____________

    a.

     

    Represents accruals for litigation in the Tobacco segment.

    b.

     

    Represents the Tobacco segment's settlement of long-standing disputes related to the Master Settlement Agreement.

     

    TABLE 5

    VECTOR GROUP LTD. AND SUBSIDIARIES

    RECONCILIATION OF TOBACCO ADJUSTED OPERATING INCOME

    AND TOBACCO ADJUSTED EBITDA

    (Unaudited)

    (Dollars in Thousands)

     

     

    LTM

     

    Year Ended

     

    Three Months Ended

     

    March 31,

     

    December 31,

     

    March 31,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

     

    Tobacco Adjusted Operating Income:

     

     

     

     

     

     

     

    Operating income from Tobacco segment

    $

    351,073

     

     

    $

    346,673

     

     

    $

    82,999

     

     

    $

    78,599

     

     

     

     

     

     

     

     

     

    Litigation settlement and judgment expense (a)

     

    18,720

     

     

     

    18,799

     

     

     

    191

     

     

     

    270

     

    Impact of MSA settlement (b)

     

    (592

    )

     

     

    (734

    )

     

     

    (169

    )

     

     

    (311

    )

    Total adjustments

     

    18,128

     

     

     

    18,065

     

     

     

    22

     

     

     

    (41

    )

     

     

     

     

     

     

     

     

    Tobacco Adjusted Operating Income

    $

    369,201

     

     

    $

    364,738

     

     

    $

    83,021

     

     

    $

    78,558

     

     

    LTM

     

    Year Ended

     

    Three Months Ended

     

    March 31,

     

    December 31,

     

    March 31,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

     

     

     

    Tobacco Adjusted EBITDA:

     

     

     

     

     

     

     

    Operating income from Tobacco segment

    $

    351,073

     

     

    $

    346,673

     

     

    $

    82,999

     

     

    $

    78,599

     

     

     

     

     

     

     

     

     

    Litigation settlement and judgment expense (a)

     

    18,720

     

     

     

    18,799

     

     

     

    191

     

     

     

    270

     

    Impact of MSA settlement (b)

     

    (592

    )

     

     

    (734

    )

     

     

    (169

    )

     

     

    (311

    )

    Total adjustments

     

    18,128

     

     

     

    18,065

     

     

     

    22

     

     

     

    (41

    )

     

     

     

     

     

     

     

     

    Tobacco Adjusted Operating Income

     

    369,201

     

     

     

    364,738

     

     

     

    83,021

     

     

     

    78,558

     

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

    5,621

     

     

     

    5,686

     

     

     

    1,312

     

     

     

    1,377

     

    Stock-based compensation expense

     

    181

     

     

     

    151

     

     

     

    57

     

     

     

    27

     

    Total adjustments

     

    5,802

     

     

     

    5,837

     

     

     

    1,369

     

     

     

    1,404

     

     

     

     

     

     

     

     

     

    Tobacco Adjusted EBITDA

    $

    375,003

     

     

    $

    370,575

     

     

    $

    84,390

     

     

    $

    79,962

     

    ____________

    a.

     

    Represents accruals for litigation in the Tobacco segment.

    b.

     

    Represents the Tobacco segment's settlement of long-standing disputes related to the Master Settlement Agreement.

     

    TABLE 6

    VECTOR GROUP LTD. AND SUBSIDIARIES

    RECONCILIATION OF REVENUES

    (Unaudited)

    (Dollars in Thousands)

     

     

     

    LTM

     

    Year Ended

     

    Three Months Ended

     

     

    March 31,

     

    December 31,

     

    March 31,

     

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

    Revenues:

     

     

     

     

     

     

     

     

    Tobacco (a)

     

    $

    1,414,690

     

     

    $

    1,424,268

     

     

    $

    324,567

     

     

    $

    334,145

     

    ____________

    a.

     

    Tobacco segment revenues include federal excise taxes of $474,268 for the last twelve months ended March 31, 2024, $486,263 for the year ended December 31, 2023, and $105,823, and $117,818 for the three months ended March 31, 2024 and 2023, respectively.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240501852371/en/

    Get the next $VGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VGR

    DatePrice TargetRatingAnalyst
    3/31/2022$12.00 → $16.00Equal Weight → Overweight
    Barclays
    11/15/2021$13.00 → $17.00Underweight → Equal Weight
    Barclays
    11/9/2021$18.00Perform → Outperform
    Oppenheimer
    9/13/2021$15.00 → $13.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $VGR
    Financials

    Live finance-specific insights

    See more
    • Vector Group Declares Quarterly Cash Dividend

      Vector Group Ltd. (NYSE:VGR) today announced that its Board of Directors has declared a regular quarterly cash dividend on its common stock of $0.20 per share. The quarterly cash dividend will be payable on September 12, 2024, to holders of record as of August 30, 2024. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240819252290/en/

      8/20/24 3:08:00 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group Reports Second Quarter 2024 Financial Results

      Montego maintains position as largest discount brand in the U.S. Second Quarter 2024 Highlights: Consolidated revenues of $371.9 million, up 1.7% or $6.3 million compared to the prior year period. Tobacco segment wholesale market share increased to 5.7% from 5.4% in the prior year period and retail market share remained at 5.8%, unchanged from the prior year period. Montego wholesale and retail market share both increased to 4.1% from 3.4% and 3.5%, respectively, in the prior year period. Operating income of $97.8 million, up 36.5% or $26.1 million compared to the prior year period. Tobacco segment operating income of $102.9 million, up 37.0% or $27.8 million compared to t

      7/31/24 4:45:00 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group to Host Second Quarter 2024 Results Conference Call

      Vector Group Ltd. (NYSE:VGR) will conduct a conference call and webcast to discuss its second quarter 2024 results on Thursday, August 1, 2024 at 8:00 a.m. (ET). Investors may access the call via live webcast at https://www.webcaster4.com/Webcast/Page/2271/50954. Please join the webcast at least 10 minutes prior to start time. A replay of the call will be available shortly after the call ends on August 1, 2024 through August 15, 2024 at https://www.webcaster4.com/Webcast/Page/2271/50954. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.

      7/25/24 8:00:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hims & Hers Health Set to Join S&P SmallCap 600

      NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com

      10/4/24 6:05:00 PM ET
      $HIMS
      $SPGI
      $VGR
      Medical/Nursing Services
      Health Care
      Finance: Consumer Services
      Finance
    • Vector Group Announces Agreement to be Acquired by JT Group

      Delivers significant value for stockholders while positioning Vector Group for long-term success Vector Group Ltd. (NYSE:VGR) today announced that it has entered into a definitive agreement to be acquired by JT Group, a global company headquartered in Tokyo, Japan, operating in tobacco, pharmaceuticals and processed food. JT Group's global tobacco business, headquartered in Geneva, Switzerland, manufactures and sells some of the world's best-known brands in over 130 markets worldwide – including Winston and Camel (outside the U.S.), as well as MEVIUS and LD. Under the terms of the agreement, JT Group will offer to acquire all outstanding shares of Vector Group common stock for $15.00 pe

      8/21/24 6:00:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group Declares Quarterly Cash Dividend

      Vector Group Ltd. (NYSE:VGR) today announced that its Board of Directors has declared a regular quarterly cash dividend on its common stock of $0.20 per share. The quarterly cash dividend will be payable on September 12, 2024, to holders of record as of August 30, 2024. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240819252290/en/

      8/20/24 3:08:00 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vector Grp upgraded by Barclays with a new price target

      Barclays upgraded Vector Grp from Equal Weight to Overweight and set a new price target of $16.00 from $12.00 previously

      3/31/22 7:41:06 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Grp upgraded by Barclays with a new price target

      Barclays upgraded Vector Grp from Underweight to Equal Weight and set a new price target of $17.00 from $13.00 previously

      11/15/21 8:00:05 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Vector Group from Perform to Outperform and set a new price target of $18.00

      11/9/21 6:13:20 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

      SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

      10/15/24 4:00:16 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

      SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

      10/7/24 8:43:24 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

      SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

      10/1/24 4:27:47 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Vector Group Ltd.

      15-12G - VECTOR GROUP LTD (0000059440) (Filer)

      10/17/24 8:00:07 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Vector Group Ltd.

      EFFECT - VECTOR GROUP LTD (0000059440) (Filer)

      10/8/24 12:15:04 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Vector Group Ltd.

      EFFECT - VECTOR GROUP LTD (0000059440) (Filer)

      10/8/24 12:15:08 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Hims & Hers Health Set to Join S&P SmallCap 600

      NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com

      10/4/24 6:05:00 PM ET
      $HIMS
      $SPGI
      $VGR
      Medical/Nursing Services
      Health Care
      Finance: Consumer Services
      Finance
    • Douglas Elliman Appoints Richard Ferrari as President and CEO of Brokerage for New York City and the Northeast Region

      Yuval Greenblatt and Alfred Renna Promoted to Senior Managing Director of Operations and Senior Managing Director of Sales, Respectively, for Flagship 575 Madison Avenue Office Douglas Elliman, one of the largest residential real estate brokerages in the United States, announced today that real estate veteran Richard Ferrari has joined the firm as President and CEO of Brokerage for New York City and the Northeast Region. In this role, Ferrari, a highly regarded industry expert, will oversee the firm's New York City resale markets, including Manhattan, Brooklyn, Riverdale and Long Island City in Queens. He will also assume responsibility for Elliman's New Jersey, Westchester, Connecticut a

      7/21/21 8:30:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group Appoints Technology Veteran Wilson L. White to its Board of Directors

      Expands Board to 10 Directors with Addition of Silicon Valley Executive Vector Group Ltd. (NYSE:VGR) (the "Company") today announced that it has appointed technology industry veteran, Wilson L. White, to its Board of Directors, effective immediately. Mr. White currently serves as Senior Director of Government Affairs and Public Policy at Google. With Mr. White's appointment, Vector Group's Board expands to 10 directors. "With many years of experience in the technology industry, including government relations and legal expertise, Wilson brings to the Board a unique skillset that will further strengthen Vector Group's commitment to staying at the forefront of our business' rapidly-evolving

      6/22/21 8:00:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Watkins Barry returned $225,000 worth of shares to the company (15,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

      4 - VECTOR GROUP LTD (0000059440) (Issuer)

      10/7/24 9:41:06 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Bell Marc N was granted 164,500 shares and returned $5,100,000 worth of shares to the company (340,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

      4 - VECTOR GROUP LTD (0000059440) (Issuer)

      10/7/24 9:14:02 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Sharpe Jean E returned $225,000 worth of shares to the company (15,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

      4 - VECTOR GROUP LTD (0000059440) (Issuer)

      10/7/24 9:08:43 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care